Biologics
Advanced biological products for complex medical needs
Overview
Daktari Biotechnology's biologics division focuses on developing complex biological products including proteins, antibodies, and other advanced therapies for treating chronic and acute conditions.
Our Biologics Portfolio
Our portfolio includes monoclonal antibodies, recombinant proteins, biosimilars, and cell and gene therapies.
Recombinant Proteins
Our recombinant protein portfolio includes insulin, erythropoietin, and growth factors for treating various conditions including diabetes, anemia, and growth disorders.
Monoclonal Antibodies
We develop therapeutic monoclonal antibodies for cancer, autoimmune disorders, and infectious diseases, providing targeted treatment options with reduced side effects.
Biosimilars
Our biosimilar program focuses on developing cost-effective alternatives to existing biologics, improving access to essential treatments in resource-limited settings.
Cell and Gene Therapies
Our advanced research in cell and gene therapies aims to develop innovative treatments for genetic disorders and degenerative diseases.
Our Approach
Advanced Expression Systems
We utilize cutting-edge expression systems, including mammalian, bacterial, and insect cell platforms, to produce complex biological molecules with high fidelity and yield.
Innovative Bioprocessing
Our state-of-the-art bioprocessing facilities employ the latest technologies in upstream and downstream processing to ensure consistent, high-quality biologics production.
Comprehensive Characterization
We employ advanced analytical techniques to thoroughly characterize our biologics, ensuring their safety, efficacy, and stability throughout their lifecycle.
Regulatory Expertise
Our regulatory team has extensive experience navigating the complex regulatory landscape for biologics, ensuring compliance with international standards and facilitating timely approvals.
Current Projects
Insulin Biosimilar
Developing a cost-effective insulin biosimilar to improve access to this essential medication for diabetes management in resource-limited settings.
Phase III Clinical Trials
Therapeutic Antibody for Cancer
Developing a novel monoclonal antibody targeting specific cancer markers prevalent in African populations, with potential applications in breast and colorectal cancers.
Preclinical Development
Erythropoietin Biosimilar
Creating a biosimilar version of erythropoietin for treating anemia associated with chronic kidney disease and cancer chemotherapy.
Phase II Clinical Trials
Our Solutions
Biologics Capabilities
- Protein Engineering
- Cell Line Development
- Bioprocess Development
- Analytical Characterization
- Stability Testing
- Regulatory Support